Plasmodium falciparum Plasmepsin 2 Duplications, West Africa
Juliana Inoue
1, Miguel Silva
1, Bakary Fofana, Kassim Sanogo, Andreas Mårtensson, Issaka Sagara, Anders Björkman, Maria Isabel Veiga, Pedro Eduardo Ferreira, Abdoulaye Djimde, and José Pedro Gil
Author affiliations: Uppsala University, Uppsala, Sweden (J. Inoue, A. Mårtensson, J.P. Gil); University of Minho, Braga, Portugal (M. Silva, M.I. Veiga, P.E. Ferreira); University of Science, Techniques, and Technologies of Bamako, Bamako, Mali (B. Fofana, K. Sanogo, I. Sagara, A. Djimde); Karolinska Institutet, Stockholm, Sweden (A. Björkman, J.P. Gil); Universidade de Lisboa, Lisbon, Portugal (J.P. Gil)
Main Article
Figure
Figure. Timeline distribution of Plasmodium falciparum pfpm2 copy number status during post–DHA/PPQ treatment follow-up for artemisinin combination therapy efficacy trials conducted by the West African Network for Antimalarial Drugs, Mali, Burkina Faso, and Guinea, October 2011–February 2016. Dark gray bar highlights the period (3 d) of treatment; lighter, longer gray bars represent PPQ average half-life (≈20 d). Circles represent recurrent infections; white circles indicate 1 pfpm2 copy, and gray circles indicate 2 pfpm2 copies. DHA/PPQ, dihydroartemisinin/piperaquine; PPQ, piperaquine.
Main Article
Page created: July 18, 2018
Page updated: July 18, 2018
Page reviewed: July 18, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.